Oslo, Norway

Anne Spurkland

This inventor holds 1 USPTO granted patent. Top assignee: Medinnova Sf. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anne Spurkland. Retrieved from https://idiyas.com/inventor/anne-spurkland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anne Spurkland: Innovator in Nucleic Acid Isolation

Introduction

Anne Spurkland is a notable inventor based in Oslo, Norway. She has made significant contributions to the field of molecular biology, particularly in the isolation of nucleic acids. Her work has implications for various applications in research and medicine.

Latest Patents

Anne holds a patent for the isolation of nucleic acid. This innovation is crucial for advancements in genetic research and diagnostics. Her patent demonstrates her expertise and commitment to enhancing scientific methodologies.

Career Highlights

Anne is currently associated with Medinnova SF, where she continues to push the boundaries of scientific research. Her role at the company allows her to collaborate with other experts in the field, furthering her impact on molecular biology.

Collaborations

One of her notable collaborators is Jarle Breivik. Together, they work on projects that aim to improve techniques in nucleic acid research.

Conclusion

Anne Spurkland is a pioneering inventor whose work in nucleic acid isolation is shaping the future of molecular biology. Her contributions are invaluable to the scientific community and continue to inspire innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…